Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Pediatric Evans syndrome is associated with a high frequency of potentially damaging variants in immune genes

Blood (2019) 134 (1): 9–21.

https://doi.org/10.1182/blood-2018-11-887141

Published: 2019

Includes: Supplemental data

Journal Articles

Allogeneic Stem Cell Transplantation in First Chronic Phase CML during the Last Decade: Retrospective Analysis of the National SFGM-TC Registry

Franck-Emmanuel Nicolini, MD PhD, Valerie Coiteux, MD, Gerard Socie, MD PhD, Didier Blaise, MD PhD, Eric Deconinck, MD PhD, Patrice Chevallier, MD PhD, Pierre Simon Rohrlich, Stephanie Nguyen, MD PhD, Thierry Lamy, MDPhD, Jean-Henri Bourhis, MD PhD, Marie-Thérèse Rubio, MD PhD, Felipe Suarez, MD PhD, Jerome Cornillon, MD, Gandhi Damaj, MD, Natacha Maillard, MD, Noel Milpied, MD PhD, Patrice Ceballos, MD, Mohamad Mohty, MD PhD, Claude-Eric Bulabois, MD, Bruno Lioure, MD, Gerard Michel, MD, Norbert Ifrah, Yves Beguin, MD PhD, Anne Huynh, MD, Nathalie Contentin, MD, Jacques-Olivier Bay, MD PhD, Yves Bertrand, MD PhD, Yves Perel, MD, Jean-Hugues Dalle, MD PhD Prof., Gaelle Guillerm, MD, jean-Valere Malfuson, MD, Aude Marie-Cardine, MD, Mauricette Michallet, MD PhD, Nicole Raus, Data Manager, Marie Balsat, MD, Helene Labussiere, MD, Regis Peffault De Latour, MD PhD, Ibrahim Yakoub-Agha, MD PhD

Blood (2016) 128 (22): 3476.

https://doi.org/10.1182/blood.V128.22.3476.3476

Published: 2016

Journal Articles

Safety and Efficacy of Blinatumomab Used in Children with B-Precursor Acute Lymphoblastic Leukemia (ALL) Treated in French Hematological Centers

Anne-Flore Derache, MD, Fanny Rialland, MD, Gerard Michel, MD, Yves Perel, MD, Virginie Gandemer, MD PhD, Pascale Blouin, MD, Odile Minckes, MD, Arnaud Petit, MD PhD, Andre Baruchel, MD PhD, Benoit Brethon, MD

Blood (2016) 128 (22): 5190.

https://doi.org/10.1182/blood.V128.22.5190.5190

Published: 2016

Journal Articles

Daunorubicin or Not During the Induction Treatment of Childhood Standard-Risk B-Cell Precursor Acute Lymphoblastic Leukemia (SR-BCP-ALL): The Randomized Fralle 2000-A Protocol

Blood (2012) 120 (21): 135.

https://doi.org/10.1182/blood.V120.21.135.135

Published: 2012

Journal Articles

Excellent Prognosis of Late Relapses of ETV6/RUNX1 Childhood Acute Lymphoblastic Leukemia: Lessons From the FRALLE 93 Protocol

Virginie Gandemer, MD, PhD, Sylvie Chevret, Arnaud Petit, Christiane Vermylen, MD, PhD, Thierry Leblanc, MD, Gerard Michel, Claudine Schmitt, Odile Lejars, Jean-Pierre Vannier, Francois Demeocq, Brigitte Bader-Meunier, Francoise Bernaudin, Yves Perel, MD, PhD, Marie-Francoise Auclerc, Jean Michel Cayuela, MD, PhD, Guy Leverger, MD, PhD, Andre Baruchel

Blood (2011) 118 (21): 1508.

https://doi.org/10.1182/blood.V118.21.1508.1508

Published: 2011

Journal Articles

Revisiting Splenectomy in Childhood Chronic Immune Thrombocytopenia At the Era of New Therapies: The French Experience

Nathalie Aladjidi, MD, Raoul Santiago, MD, Pondarré Corinne, MD, Anne Lambilliote, MD, Guy Leverger, MD, PhD, Claire Godard Sebillotte, MD, Helder Fernandes, PdD, Hervé Chambost, MD, PhD, Pierre Rohrlich, MD, PhD, Marlène Pasquet, MD, Thierry Leblanc, MD, Yves Perel, MD, PhD

Blood (2011) 118 (21): 2227.

https://doi.org/10.1182/blood.V118.21.2227.2227

Published: 2011

Journal Articles

Rituximab in 42 Cases of French Childhood Auto-Immune Haemolytic Anaemia: High Efficiency but Caution Required

Stéphane Ducassou, Nathalie Aladjidi, MD, Corinne Pondarre, Thierry Leblanc, MD, Hervé Chambost, MD, PhD, Armari-Alla Corinne, Pasquet Marlene, Helder Fernandes, PdD, Bayart Sophie, Piguet Christophe, Fouyssac Fanny, Monpoux Fabrice, Odile Lejars, Jeziorski Eric, Corinne Guitton, Guy Leverger, MD, PhD, Yves Perel, MD, PhD

Blood (2011) 118 (21): 2100.

https://doi.org/10.1182/blood.V118.21.2100.2100

Published: 2011

Journal Articles

Excellent Prognosis of Children with ETV6-RUNX1 Positive (+) Acute Lymphoblastic Leukemia (ALL) in the FRALLE 2000 Protocol.

Virginie Gandemer, MD, Marie-Françoise Auclerc, MD, Arnaud Petit, MD, Benoît Brethon, MD, Paola Ballerini, Gerard Michel, MD, PhD, Yves Perel, MD, PhD, Anne Auvrignon, MD, Francoise Mechinaud, Claudine Schmitt, Pascale Schneider, Christiane Vermylen, Odile Lejars, MD, Thierry Leblanc, MD, Jean Gabert, MD, PhD, Elizabeth Macintyre, MD, PhD, Jean-Michel Cayuela, PharmD, PhD, Guy Leverger, MD, Andre Baruchel, MD

Blood (2009) 114 (22): 1628.

https://doi.org/10.1182/blood.V114.22.1628.1628

Published: 2009

Journal Articles

New Insights Into Autoimmune Hemolytic Anemia of children : A French National Observational study of 268 Children.

Nathalie Aladjidi, MD, Thierry Leblanc, MD, Guy Leverger, MD, PhD, Marie Quitterie Picat, Gerard Michel, MD, PhD, Brigitte Bader-Meunier, MD, Yves Bertrand, MD, PhD, Alain Fischer, MD, PhD, Genevieve Chene, MD, PhD, Yves Perel, MD, PhD

Blood (2009) 114 (22): 3017.

https://doi.org/10.1182/blood.V114.22.3017.3017

Published: 2009

Journal Articles

High-Dose Methotrexate Seems to Benefit Only to Standard-Risk BCP-ALL Patients with Good Early Response to Chemotherapy: Final Analysis of the FRALLE93B Study

Blood (2008) 112 (11): 10.

https://doi.org/10.1182/blood.V112.11.10.10

Published: 2008

Journal Articles

Minimal Residual Disease in High and Very High Risk ALL (HR/VHR-ALL) at the End of Induction (EOI) in FRALLE 2000 B and T Protocols.

Blood (2007) 110 (11): 1427.

https://doi.org/10.1182/blood.V110.11.1427.1427

Published: 2007

Journal Articles

Two Decades of Progresses in Adolescents with Acute Lymphoblastic Leukemia (ALL) Treated in the FRALLE Protocols: Adolescence Is No More a Bad Prognostic Feature If an Intensive Chemotherapy Is Applied.

Andre Baruchel, MD, Marie-Françoise Auclerc, MD, Yves Perel, MD, Françoise Mechinaud, MD, Anne Auvrignon, MD, Claudine Schmitt, MD, Christophe Piguet, MD, Odile Lejars, MD, Christian Berthou, MD, François Demeocq, MD, Pascale Schneider, MD, Virginie Gandemer, MD, Gérard Michel, MD, Jean-Michel Cayuela, Pharm D, Thierry Leblanc, MD, Guy Leverger, MD, the FRALLE Group

Blood (2006) 108 (11): 1852.

https://doi.org/10.1182/blood.V108.11.1852.1852

Published: 2006

Journal Articles

Treatment of Childhood T Cell Lymphoblastic Lymphoma (TLL), Results of the SFOP LMT96.

Christophe Bergeron, MD, David Perol, MD, Helene Pacquement, MD, Yves Perel, MD, Carole Coze, MD, Virginie Gandemer, MD, Jean P. Vannier, MD, Francois Mechinaud, MD, Claudine Schmitt, MD, Guy Leverger, MD, Andre Baruchel, MD, Catherine Patte, MD

Blood (2005) 106 (11): 3326.

https://doi.org/10.1182/blood.V106.11.3326.3326

Published: 2005

Journal Articles

SFCE (Societe Francaise des Cancers de l’Enfant) Recommendations for the Management of Tumor Lysis Syndrome (TLS): A Validation Survey.

Yves Bertrand, Anne Auvrignon, MD, Brigitte Nelken, MD, Valérie Mialoux, MD, Francoise Mechinaud, MD, Catherine Patte, MD, Dominique Plantaz, MD, Nathalie Le Guyader, MD, Marisol Urbieta, MD, Yves Perel, Andre Baruchel9, Guy Leverger

Blood (2005) 106 (11): 3122.

https://doi.org/10.1182/blood.V106.11.3122.3122

Published: 2005

Journal Articles

Autoimmune Hemolytic Anemia (AIHA) in Children: A French Observational Study of 171 Patients for the French Society of Pediatric Hematology and Immunology (SHIP).

Nathalie Aladjidi, Antoine Pariente, Thierry Leblanc, Brigitte Bader Meunier, Yves Bertrand, Gerard Michel, Francoise Ledeist, Yves Colin, Genevieve Chene, Brigitte Nelken, Guy Leverger, Yves Perel

Blood (2005) 106 (11): 1684.

https://doi.org/10.1182/blood.V106.11.1684.1684

Published: 2005

Journal Articles

A Plateau after 30 Months of Follow-Up in B -Lineage Childhood Acute Lymphoblastic Leukemia (ALL) with t(1;19)(q23;p13)/E2A-PBX1?.

André Baruchel, MD, Sylvie Chevret, MD, PhD, Anne Auvrignon, MD, Paola Ballerini, MD, PhD, Gérard Michel, MD, Jean Gabert, MD, PhD, Christiane Vermylen, MD, Yves Perel, MD, Chrystèle Bilhou-Nabera, MD, Odile Lejars, MD, Claudine Schmitt, MD, Pierre Jonveaux, MD, PhD, Jean Soulier, MD, PhD, Jacqueline Vandenaker, MD, Marie-Françoise Auclerc, MD, Thierry Leblanc, MD, Guy Leverger, MD, for the FRALLE Group

Blood (2005) 106 (11): 1441.

https://doi.org/10.1182/blood.V106.11.1441.1441

Published: 2005

Journal Articles

Minimal Residual Disease (MRD) at the End of Induction (EOI) after a Three or Four-Drug Induction Regimen for Childhood Standard-Risk B-Cell Precursor Acute Lymphoblastic Leukemia (SR-BCP-ALL): Interim Results of the FRALLE 2000-A Protocol.

Blood (2004) 104 (11): 1105.

https://doi.org/10.1182/blood.V104.11.1105.1105

Published: 2004

Journal Articles

Childhood Standard-Risk B-Cell Precursor Acute Lymphoblastic Leukemia (SR-BCP-ALL): Toxicity and Efficacy Interim Results of the FRALLE 2000-A Protocol.

Blood (2004) 104 (11): 1952.

https://doi.org/10.1182/blood.V104.11.1952.1952

Published: 2004

Journal Articles

Impact of HOX11L2 and TAL1/SCL Expression in T-Cell Acute Lymphoblastic Leukaemia (T-ALL): Results of the FRALLE 93 Protocol.

Paola Ballerini, Jean-michel Cayuela, Vahid Asnafi, Sylvie Fasola, Marie-francoise Auclerc, Yves Perel, Odile Lejars5, Marianne Debre6, Gerard Michel7, Virginie Gandemer8, Brigitte Pautard9, Thierry Leblanc, Elizabeth Macintyre, Guy Leverger, Andre Baruchel, Judith Landman-Parker

Blood (2004) 104 (11): 2047.

https://doi.org/10.1182/blood.V104.11.2047.2047

Published: 2004

Journal Articles

Intermediate Dose Methotrexate in Low-Risk Acute Lymphoblastic Leukemia. Results of the FRALLE 93A Protocol.

Yves Perel, Hervé Chambost, Virginie Gandemer, Thierry Leblanc, Schneider Pascale, Schmitt Claudine, Mariane Debré, Christiane Vermylen, Gérard Couillault, Jean-Paul Lamagnere, Marie-Françoise Auclerd, Guy Leverger, André Baruchel, the FRALLE group

Blood (2004) 104 (11): 1949.

https://doi.org/10.1182/blood.V104.11.1949.1949

Published: 2004

NARROW

Pediatric Evans syndrome is associated with a high frequency of potentially damaging variants in immune genes

Allogeneic Stem Cell Transplantation in First Chronic Phase CML during the Last Decade: Retrospective Analysis of the National SFGM-TC Registry

Safety and Efficacy of Blinatumomab Used in Children with B-Precursor Acute Lymphoblastic Leukemia (ALL) Treated in French Hematological Centers

Daunorubicin or Not During the Induction Treatment of Childhood Standard-Risk B-Cell Precursor Acute Lymphoblastic Leukemia (SR-BCP-ALL): The Randomized Fralle 2000-A Protocol

Excellent Prognosis of Late Relapses of ETV6/RUNX1 Childhood Acute Lymphoblastic Leukemia: Lessons From the FRALLE 93 Protocol

Revisiting Splenectomy in Childhood Chronic Immune Thrombocytopenia At the Era of New Therapies: The French Experience

Rituximab in 42 Cases of French Childhood Auto-Immune Haemolytic Anaemia: High Efficiency but Caution Required

Excellent Prognosis of Children with ETV6-RUNX1 Positive (+) Acute Lymphoblastic Leukemia (ALL) in the FRALLE 2000 Protocol.

New Insights Into Autoimmune Hemolytic Anemia of children : A French National Observational study of 268 Children.

High-Dose Methotrexate Seems to Benefit Only to Standard-Risk BCP-ALL Patients with Good Early Response to Chemotherapy: Final Analysis of the FRALLE93B Study

Minimal Residual Disease in High and Very High Risk ALL (HR/VHR-ALL) at the End of Induction (EOI) in FRALLE 2000 B and T Protocols.

Two Decades of Progresses in Adolescents with Acute Lymphoblastic Leukemia (ALL) Treated in the FRALLE Protocols: Adolescence Is No More a Bad Prognostic Feature If an Intensive Chemotherapy Is Applied.

Treatment of Childhood T Cell Lymphoblastic Lymphoma (TLL), Results of the SFOP LMT96.

SFCE (Societe Francaise des Cancers de l’Enfant) Recommendations for the Management of Tumor Lysis Syndrome (TLS): A Validation Survey.

Autoimmune Hemolytic Anemia (AIHA) in Children: A French Observational Study of 171 Patients for the French Society of Pediatric Hematology and Immunology (SHIP).

A Plateau after 30 Months of Follow-Up in B -Lineage Childhood Acute Lymphoblastic Leukemia (ALL) with t(1;19)(q23;p13)/E2A-PBX1?.

Minimal Residual Disease (MRD) at the End of Induction (EOI) after a Three or Four-Drug Induction Regimen for Childhood Standard-Risk B-Cell Precursor Acute Lymphoblastic Leukemia (SR-BCP-ALL): Interim Results of the FRALLE 2000-A Protocol.

Childhood Standard-Risk B-Cell Precursor Acute Lymphoblastic Leukemia (SR-BCP-ALL): Toxicity and Efficacy Interim Results of the FRALLE 2000-A Protocol.

Impact of HOX11L2 and TAL1/SCL Expression in T-Cell Acute Lymphoblastic Leukaemia (T-ALL): Results of the FRALLE 93 Protocol.

Intermediate Dose Methotrexate in Low-Risk Acute Lymphoblastic Leukemia. Results of the FRALLE 93A Protocol.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only